BlackRock
SGMO

BlackRock’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

BlackRock’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Sell
4,547,848
-23,938
-0.5% -$9.53K ﹤0.01% 4299
2025
Q4 		$1.92M Buy
4,571,786
+15,578
+0.3% +$8.26K ﹤0.01% 4126
2025
Q3 		$3.07M Sell
4,556,208
-252,500
-5% -$136K ﹤0.01% 3964
2025
Q2 		$2.6M Sell
4,808,708
-636,310
-12% -$378K ﹤0.01% 3995
2025
Q1 		$3.57M Buy
5,445,018
+251,714
+5% +$267K ﹤0.01% 3772
2024
Q4 		$5.3M Buy
5,193,304
+1,564,235
+43% +$2.86M ﹤0.01% 3705
2024
Q3 		$3.14M Sell
3,629,069
-1,073,869
-23% -$787K ﹤0.01% 3863
2024
Q2 		$1.69M Sell
4,702,938
-8,574,699
-65% -$4.63M ﹤0.01% 4014
2024
Q1 		$8.9M Sell
13,277,637
-818,228
-6% -$593K ﹤0.01% 3400
2023
Q4 		$7.66M Sell
14,095,865
-1,701,091
-11% -$784K ﹤0.01% 3516
2023
Q3 		$9.48M Sell
15,796,956
-92,020
-0.6% -$98.5K ﹤0.01% 3364
2023
Q2 		$20.7M Buy
15,888,976
+48,282
+0.3% +$66K ﹤0.01% 3024
2023
Q1 		$27.9M Buy
15,840,694
+481,253
+3% +$1.37M ﹤0.01% 2802
2022
Q4 		$48.2M Buy
15,359,441
+1,094,983
+8% +$4.25M ﹤0.01% 2489
2022
Q3 		$69.9M Buy
14,264,458
+1,898,292
+15% +$9.75M ﹤0.01% 2203
2022
Q2 		$51.2M Buy
12,366,166
+751,070
+6% +$3.25M ﹤0.01% 2484
2022
Q1 		$67.5M Sell
11,615,096
-47,784
-0.4% -$284K ﹤0.01% 2389
2021
Q4 		$87.5M Buy
11,662,880
+372,615
+3% +$3.24M ﹤0.01% 2295
2021
Q3 		$102M Buy
11,290,265
+1,506,297
+15% +$14.9M ﹤0.01% 2203
2021
Q2 		$117M Sell
9,783,968
-4,046
-0% -$45.8K ﹤0.01% 2158
2021
Q1 		$123M Buy
9,788,014
+221,599
+2% +$2.99M ﹤0.01% 2067
2020
Q4 		$149M Sell
9,566,415
-325,458
-3% -$3.81M ﹤0.01% 1819
2020
Q3 		$93.5M Sell
9,891,873
-453,643
-4% -$4.91M ﹤0.01% 1929
2020
Q2 		$92.7M Buy
10,345,516
+968,180
+10% +$8.98M ﹤0.01% 1882
2020
Q1 		$59.7M Sell
9,377,336
-156,935
-2% -$1.16M ﹤0.01% 1950
2019
Q4 		$79.8M Sell
9,534,271
-62,130
-0.6% -$571K ﹤0.01% 2083
2019
Q3 		$86.8M Buy
9,596,401
+164,223
+2% +$1.84M ﹤0.01% 1978
2019
Q2 		$102M Buy
9,432,178
+1,098,030
+13% +$11.7M ﹤0.01% 1901
2019
Q1 		$79.5M Sell
8,334,148
-96,690
-1% -$988K ﹤0.01% 2014
2018
Q4 		$96.8M Buy
8,430,838
+108,527
+1% +$1.35M ﹤0.01% 1825
2018
Q3 		$141M Buy
8,322,311
+239,190
+3% +$3.64M 0.01% 1731
2018
Q2 		$115M Buy
8,083,121
+1,391,067
+21% +$23.1M 0.01% 1852
2018
Q1 		$127M Sell
6,692,054
-179,455
-3% -$3.84M 0.01% 1677
2017
Q4 		$113M Buy
6,871,509
+138,348
+2% +$2.06M 0.01% 1799
2017
Q3 		$101M Buy
6,733,161
+1,108,598
+20% +$12.3M 0.01% 1850
2017
Q2 		$49.5M Buy
5,624,563
+5,712
+0.1% +$36.6K ﹤0.01% 2263
2017
Q1 		$29.2M Buy
5,618,851
+5,613,627
+107,458% +$22.5M ﹤0.01% 2527
2016
Q4 		$16K Sell
5,224
-773
-13% -$2.81K ﹤0.01% 3304
2016
Q3 		$29K Sell
5,997
-800
-12% -$4.07K ﹤0.01% 3185
2016
Q2 		$39K Sell
6,797
-447
-6% -$2.85K ﹤0.01% 3049
2016
Q1 		$44K Buy
7,244
+5,279
+269% +$31.7K ﹤0.01% 2434
2015
Q4 		$18K Hold
1,965
– – ﹤0.01% 2635
2015
Q3 		$11K Hold
1,965
– – ﹤0.01% 2690
2015
Q2 		$22K Sell
1,965
-103
-5% -$1.33K ﹤0.01% 2365
2015
Q1 		$33K Hold
2,068
– – ﹤0.01% 2129
2014
Q4 		$31K Hold
2,068
– – ﹤0.01% 2162
2014
Q3 		$22K Hold
2,068
– – ﹤0.01% 2287
2014
Q2 		$31K Buy
2,068
+445
+27% +$6.4K ﹤0.01% 2160
2014
Q1 		$29K Buy
1,623
+140
+9% +$2.7K ﹤0.01% 2175
2013
Q4 		$21K Buy
1,483
+120
+9% +$1.38K ﹤0.01% 2344
2013
Q3 		$14K Hold
1,363
– – ﹤0.01% 2448
2013
Q2 		$11K Buy
+1,363
New +$11.9K ﹤0.01% 2590

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

BlackRock's SGMO Position: Q1 2026 in Review

BlackRock reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 0.52% in Q1 2026, selling an estimated $9.53K and leaving 4,547,848 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #4299.

BlackRock first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $149M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • BlackRock held 4,547,848 shares of SANGAMO THERAPEUTICS INC worth $1.12M as of Q1 2026.
  • BlackRock sold 23,938 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $9.53K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4299 holding.
  • BlackRock first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • BlackRock's SANGAMO THERAPEUTICS INC position peaked at $149M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.